Informatics
Disruptive precision medicine technology conquering inflammation and diabetes
Synthetic IBD Patients
Synthetic patient cohorts are key components in the design of in silico clinical trials. A virtual population group ideally reflects the individual diversity and variability plus characteristics that represent a clinical cohort population. The virtual population can be extremely useful in identifying the broad range of responses which are otherwise hard to predict in a clinical trial.
A larger synthetic population of patient avatars was generated based on an expert guided random variation from the typical cases of IBD patients undergoing treatments of placebo, GED-0301, Anti-TNF-alpha, and BT-11.
Informatics
Disruptive precision medicine technology conquering inflammation and diabetes
iMed: intelligent Medicine
The advanced analytics platform, intelligent Medicine (iMED), is engineered to model from molecules and cells to clinical cohorts of patients with inflammatory bowel disease (IBD).
iMED is the first multiscale modeling platform that ties together Ordinary Differential Equation (ODE), Stochastic Differential Equation (SDE), Partial Differential Equation (PDE), Agent-Based Model (ABM), and Artificial Intelligence (AI) modules into a single cohesive IBD model capable of parallel processing.
iMed is able to elucidate hidden, unforeseen linkages between spatiotemporal simulation changes with clinical disease scoring methods through image analysis of endoscopies. Combined with expert image analysis of real patient’s gut endoscopic images, advanced machine learning algorithms provide a foundation for clinical utility of our iMED models.
Contact
Contact
We are enthusiastic about applying our expertise to address critical health issues and are actively seeking new collaborations. To discuss a potential opportunity or to learn more about Biotherapeutics Inc., please contact us below.
Services
Preclinical Efficacy Services
Biotherapeutics Inc. offers a broad array of preclinical services in mouse, rats and pigs for product testing, mechanism of action validation studies, and hypothesis–driven and hypothesis-generating in vivo experimentation. All our preclinical animal models are set up in Institutional Animal Care and Use Committee (IACUC)-approved facilities. Animals are housed in a state-of-art facility that can accommodate large projects as well as both BL-1 and BL-2 experiments.
BTI offers pre-clinical efficacy animals models of the following diseases:
Inflammatory Bowel Disease (IBD)
Inflammatory bowel disease (IBD) is characterized by two major clinical manifestations: Crohn’s disease (CD) and ulcerative colitis (UC). CD can affect any region of the gastrointestinal (GI) tract from mouth to anus. In contrast, UC causes acute colonic inflammation.
BTI offers expertise and services in mouse models of IBD, such as trinitrobenzene sulfonic acid (TNBS), dextran sodium sulfate (DSS)-induced colitis, pan-enteritis due to the deficiency of interleukin-10 (IL-10 KO) and CD4+ T cell-induced colitis in adoptive transfer models. Whereas TNBS and DSS-induced colitis represent the more acute and faster induction of colonic tissue damage, the IL-10 KO and the CD4+ T cell induced colitis represent chronic models of IBD. We have also developed a model of inflammation-driven colorectal cancer (CRC) following treatment of mice with azoxymethane and DSS.
BTI provides expertise and resources in these four preclinical models with more than 10 years of experience and results published in top gastroenterology journals.
BTI can provide data on:
- Gut histological and immunohistochemical changes
- Transcriptomic analyses (RNAseq, ChipSep, miRNA)
- Preclinical efficacy, tolerability and weight loss
- Cellular and molecular profiling
Type1 and Type 2 Diabetes
Type 1 Diabetes
Type 1 diabetes (T1D) is an immune-mediated disease that afflicts three million Americans. Each year, more than 15,000 children and 15,000 adults are diagnosed with T1D in the U.S. The rate of T1D incidence among children under age 14 is estimated to increase by 3% annually worldwide. T1D patients require insulin injections to stay alive, but they do not cure the disease or prevent its serious side effects.
BTI can provide expertise on two models of type 1 diabetes: the NOD and the STZ-induced model of type 1 diabetes. NOD mice, specially females, develop insulitis at around 3-4 weeks of age. This model dominates the literature as the autoimmune model of choice. Alternatively, diabetes can be also induced in mice by using streptozotocin (STZ), a compound that has a preferential toxicity towards pancreatic beta cells.
Type 2 Diabetes
About 28.3 million Americans have type 2 diabetes (T2D) and over 40.1% of middle-aged adults have pre-diabetes, a condition characterized by impaired glucose tolerance, systemic inflammation and insulin resistance. Current anti-diabetic medications are effective in improving insulin sensitivity, but their chronic administration has significant side effects such as cardiovascular complications, hepatotoxicity, weight gain, fluid retention, and bladder tumors.
BTI can provide expertise and experience in mouse models of type 2 diabetes: the db/db and the diet-induced obesity (DIO) models. Within 6 weeks of age, db/db mice developed significant obesity, fasting hyperglycemia, and hyperinsulinemia. On the other hand, the DIO model is induced by administering mice with a high-fat diet for certain amount of time. BTI has expertise in both models and a track record of publications published in top journals.
For both type 1 and type 2, BTI can provide data on:
- Clinical Activity and disease progression• Histology and immunohistochemistry
- Glucose and Insulin levels (FBG, FBI, GTT, ITT)
- Therapeutic efficacy
- Immunological assays and flow cytometry (also in abdominal and subcutaneous white adipose tissue)
Infectious Diseases: Respiratory Pathogens
BTI has been working on Influenza models with several strains, being able to develop lung damage (i.e., epithelial necrosis, leucocyte infiltration), weight loss 10-20% and clinical disease. The virus strains we are using in mouse challenge studies include:
- H1N1 strain A/Puerto Rico/8/34 (PR8)
- H3N2 strain A/Udorn/72
- H1N1 strain A/California/07/2009
BTI can provide data on:
- Viral disease progression, weight loss
- Vaccine and therapeutic efficacy
- Viral titers
- Histology and immunohistochemistry
- Immunological assays and flow cytometry
- LD50 studies
Infectious Diseases: Gastrointestinal Pathogens
Yearly outbreaks of several pathotypes of E. coli, Salmonella, and other enteric pathogens incur medical costs, lost productivity and even premature death, with total expenses exceeding $6.9 billion per year. A closer comprehension of the mechanisms of action underlying immune responses to enteric pathogens will lead to the development of more efficacious vaccines and immunotherapeutics. Through the Modeling Immunity to Enteric Pathogens program, BTI has built capabilities in modeling gut enteric infections.
BTI can reproduce and validate the following infectious disease models:
Enteroaggregative Escherichia coli (EAEC)
- JM221 strain
- 042 strain
Helicobacter pylori
- European 26695 strain
- African J99 strain
- SS1 strain
Clostridium difficile• UVA13 strain
- VPI 11186 strain
- 10463 strain
Services
Pig Studies
Interested in Pig Studies?
The BTI team has ample experience establishing pig models of infectious and immune-mediated diseases, including inflammatory bowel disease (IBD) and infections caused by enteric or respiratory pathogens. As opposed to mice, pigs offer a physiological composition more comparable to humans. Their mucosal immune system is an ideal model for studying the complexity of the human immune system and how it responds to inflammation, infection and injury. Preclinical studies using pigs lay the groundwork for an informed design of human clinical trials.
Our BTI facilities and animals:
- Internal Institutional Animal Care and Use Committee (IACUC)
- AAALAC-accredited swine facility
- Biosafety level 1 (ABSL1) and ABSL2 studies
- 16 independent experimental housing rooms, each with eight-pig capacity
- Fully equipped surgical room for onsite collection of specimens
- Superior husbandry for pigs spanning all ages of the life cycle
- Gnobiotic swine litters available
- On-site veterinarians
- Routine procedures: weights, fecal samples, venipuncture, injections, immunizations, orogastric infections and intubation
Active monitoring post-challenge is performed to ensure the well-being of the animals and provide an assessment of disease activity progression throughout the duration of the experiment. Peripheral blood collection is performed on a regular basis as a means of analyzing the time course of an infection. Execution of specific expected goals is met with superior efficiency in a timely manner while maintaining detailed attention to our animals and data.
What BTI can offer
BTI can offer pig projects with the following disease models:
- Inflammatory Bowel Disease
- Neonatal models
- Enteroaggregative Escherichia coli (EAEC) infection
- Helicobacter pylori infection
- Clostridium difficile infection
- Influenza Virus infection
Contact us today and set up a session with our immunology experts.
For additional information concerning BTI’s full range of animal model services, click here.
Services
Computational Services
Developing a drug from the discovery phase to successful entry into the market can cost about $3 billion dollars on average. The process is extremely inefficient with a failure rate of about 70% due to efficacy or safety problems. At BTI we have built the infrastructure to combine informatics-driven, computational modeling and experimental approaches to advance translational medicine research and discovery.
Analyses of RNA-sequencing datasets
To identify genes that are differentially expressed between experimental contrasts, we possess an automated pipeline based off Illumina Hiseq sequencing of transcriptomes. The pipeline integrates short read alignment with interval calculations optimized for mammalian genomes, normalization, aggregation and statistical testing.
Our RNA sequencing pipeline offers analyses on:
- Biomarker discovery
- MicroRNA
- Regulator Effects
- Upstream and Downstream
- Metabolomics
- Toxicogenomics
- Causal Networks
- Network Inference and Regulators Pathway Analysis
Computational Modeling
Understanding the immune system’s dynamics requires a coherent picture of the of a complex interplay between inflammatory and regulatory immune responses at the cellular and molecular level. Computational modeling can be used to synthesize, organize and integrate diverse types of data and theoretical frameworks to help advance or rule out drug candidates in the pipeline.
BTI has a track record on computational modeling and immunoinformatics, and this knowledge is used to guide and develop computational models for our partners and clients.
Our areas of computational modeling expertise a ranges from molecular to intracellular to tissue-level modeling. We have developed automated pipelines to:
- Create large scale computational models of cellular immune responses
- Create data-driven computational models from sequencing datasets
- Create comprehensive computational models of intracellular events after drug treatment.
Our areas of expertise are:
- CD4+ T cell differentiation
- Immune responses to bacterial infections
- Immune responses to Inflammatory Bowel Disease
- Docking studies and molecular modeling
Contact us today to set up a session with our modeling experts and learn how computational modeling can help advance your products and research goals.
For additional information on NIMML at BTI’s full range of computational modeling services, click here.
Nutritionals
Safer and more effective medical foods and supplements from nature’s innovation
Gut Inflammation (PUA)
Major Health Problem
Gut Inflammation
- In 2004 Crohn’s Disease was the cause of 57,000 hospitalizations.
- Around 200,000 new cases of IBD have surfaced since 2011.
- The US spent $1.84 billion on Crohn’s and UC in 2004.
- It is estimated that 70% of Crohn’s patients eventually need surgery.
- IBS affects 25-45 million people in the US.
Take Away
Despite this growing problem, pharmaceutical manufacturers have been unable to develop medications that are safe and highly effective. Common gut inflammation treatments are a combination approach of immunosuppressants and medications for individual symptoms. These treatments have demonstrated adverse side effects, some severe.
BTI Solution
PUA Supplement
- PUA is a novel nutritional health ingredient for managing gut inflammation and necrotizing enterocolitis.
- PUA is a safe and effective choice compared to current gut inflammation treatments.
- PUA in the average diet is not enough to benefit health.
- PUA supports digestive and immune health.
Definitions
Inflammatory Bowel Disease (IBD): A cluster of chronic, inflammatory conditions that involves all or part of the digestive tract. IBD primarily includes ulcerative colitis and Crohn’s disease.
Ulcerative Colitis (UC): An IBD that causes long-lasting inflammation and ulcers in the innermost lining of the large intestine and rectum.
Crohn’s Disease: An IBD that causes inflammation of the digestive tract. The inflammation can involve different areas of the digestive tract lining — the large intestine, small intestine or both.
Irritable Bowel Syndrome (IBS): A common disorder that affects the large intestine. Unlike IBD, IBS does not cause changes in bowel tissue or increase the risk of colorectal cancer.
Nutritionals
Safer and more effective nutritional products from nature’s innovation
Glycemic Control (ABA)
Why ABA?
- The naturally occurring Abscisic Acid (ABA) maintains healthy blood sugar levels.
What is ABA?
- ABA is a hormone originally identified in plants that is naturally produced in humans and found in regular foods/diets. ABA regulates inflammation and blood glucose levels.
ABA Discoveries
- ABA promotes glucose normalization in mouse models of disease.
- Dietary ABA improves insulin sensitivity and reduces inflammation in white adipose tissue.
- High glucose levels activate endogenous ABA production from pancreatic beta cells which stimulates glucose consumption by adipocytes and myoblasts
- A single dose of ABA (extract) at approximately 1 ug/kg body weight lowered glycemia during a glucose tolerance test (GTT) study in human subjects
ABA Levels in Common Foods
Innovative Pathway - LANCL2
- ABA binds to lanthionine synthetase C-like 2 (LANCL2) and signals through Akt/mTORC2.
- Exerts anti-diabetic actions by up-regulating glucose transporter Glut4.
Significance
ABA regulates glycemia
ABA is uniquely positioned as an active food ingredient for glycemic control.
ABA is natural
ABA is safe for human consumption, found in regular diets, and has no known side effects.
ABA is effective
Supplementation of ABA has improved/maintained glycemic control in mice, rats and humans at a low dose.
Major Health Problem
Metabolic Syndrome, Diabetes and Prediabetes
- It is estimated that 34% of adults in the U.S. have metabolic syndrome.
- About 28.3 million Americans have type 2 diabetes (T2D) and over 20% of middle-aged adults have prediabetes.
- The total direct and indirect costs attributable to T2D in the United States is over $132 billion.
- As the rates of obesity and T2D in the U.S. continue to rise, an increasingly large number of people are becoming reliant on expensive oral anti-diabetic drugs with demonstrated adverse side effect.
Take Away:
Despite this growing problem, pharmaceutical manufacturers have been unable to develop medications that are safe and highly effective. Additionally, there is an unmet need for medications targeting prediabetes.
BTI Solution
ABA GRAS Food Ingredient
- ABA is an innovative health food ingredient that fills an unmet clinical need for the nutritional management of glycemic control.
- ABA is a safe alternative to current treatments for addressing glycemic control.
- ABA has numerous health benefits in diabetes and inflammation, and it was recently demonstrated that ABA is produced and released in brain tissue and may play a role in depression.
Definitions
Metabolic Syndrome: A grouping of biochemical and physiological risk factors – high blood pressure, high blood sugar, unhealthy cholesterol levels and obesity.
Prediabetes: A condition in which blood glucose levels are higher than normal but not high enough to be classified as diabetes.
Type 2 Diabetes: A metabolic disease in which the body does not properly process glucose due to inadequate insulin production and/or the body’s cells lack of response to insulin. This results in high blood glucose.
Nutritionals
Safer and more effective nutritional products from nature’s innovation
Punicic Acid (PUA)
Why PUA?
- Punicic acid (PUA) has demonstrated effectiveness in decreasing gut inflammation and improving digestive health.
What is PUA?
- PUA is a dietary lipid found in pomegranate seed oil (PSO).
BTI Discoveries
- Oral supplementation of PSO and its predominant bioactive constituent has demonstrated efficacy in suppressing gut inflammation.
- The health benefits of PUA resemble those of conjugated linoleic acid (CLA).
- PSO ameliorates intestinal inflammation in mouse models of Inflammatory Bowel Disease (IBD) and necrotizing enterocolitis (NEC).
Innovative Pathway - NLRX1
- PUA binds to nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1).
- Involved in down-regulating inflammation during bacterial and viral exposure, acute non-infectious colitis, colorectal cancer and chronic pulmonary disease.
- Demonstrated convergence between NLRX1, antimicrobial peptide production and altered microbiome ecology.
- Loss of NLRX1 during colitis causes severe mucosal damage.
Significance
PUA reduces gut Inflammation
PUA is uniquely positioned as a food ingredient for maintaining gut homeostasis and health.
Dietary PUA is too low
The low concentrations of PUA in regular diets are insufficient to induce beneficial health and dietary PUA supplementation is required.
PUA is safe
PUA is safe for human consumption and found naturally in pomegranates.
Nutritionals
Safer and more effective nutritional products from nature’s innovation
Abscisic Acid (ABA)
Why ABA?
- The naturally occurring Abscisic Acid (ABA) maintains healthy blood sugar levels.
What is ABA?
- ABA is a hormone originally identified in plants that is naturally produced in humans and found in regular foods/diets. ABA regulates inflammation and blood glucose levels.
ABA Discoveries
- ABA promotes glucose normalization in mouse models of disease.
- Dietary ABA improves insulin sensitivity and reduces inflammation in white adipose tissue.
- High glucose levels activate endogenous ABA production from pancreatic beta cells which stimulates glucose consumption by adipocytes and myoblasts
- A single dose of ABA (extract) at approximately 1 ug/kg body weight lowered glycemia during a glucose tolerance test (GTT) study in human subjects
ABA Levels in Common Foods
Innovative Pathway - LANCL2
- ABA binds to lanthionine synthetase C-like 2 (LANCL2) and signals through Akt/mTORC2.
- Exerts anti-diabetic actions by up-regulating glucose transporter Glut4.
Significance
ABA regulates glycemia
ABA is uniquely positioned as an active food ingredient for glycemic control.
ABA is natural
ABA is safe for human consumption, found in regular diets, and has no known side effects.
ABA is effective
Supplementation of ABA has improved/maintained glycemic control in mice, rats and humans at a low dose.
Nutritionals
Safer and more effective nutritional products from nature’s innovation
Nutritionals Overview
BTI Nutritionals is a division of Biotherapeutics Inc. that develops nutritional products containing “Generally Recognized as Safe” (GRAS) ingredients of natural origins. BTI’s products improve and maintain health and well-being and are subjected to the highest levels of safety and quality.
Food Ingredients for Health Promotion
Glycemic Control
BTI’s active food ingredient, Abscisic Acid, has been thoroughly researched and scientifically proven to help maintain healthy blood sugar levels. ABA improves glucose tolerance and insulin levels in individuals with normal and high blood sugar.
Technology and Products
- Take a look at the the Abscisic and Punicic acid pages to learn more about the innovate pathways we are targeting for health promotion!
- Click on Gut inflammation and Glycemic Control pages to see the health benefits of our current nutritional products!
Informatics
Disruptive precision medicine technology conquering inflammation and diabetes
Informatics Technology
The precision medicine informatics division at Biotherapeutics Inc has made it a priority to tackle the immensely complex challenge of discovering and validating new safer and more efficacious treatments for human diseases.
Problems with Current Drug Development Process
Developing a new medicine takes an average of 10-15 years. Of the tens of thousands of compounds screened, only one is approved.
How We Solve It
Our informatics technology platform is constructed and maintained by a team of outstanding immunologists, data scientists, computational modelers, bioinformaticians and software developers in order to address the comprehensive needs of precision medicine and conquer diseases with data.
Under our informatics umbrella, we incorporate a systems-wide analysis of massively interacting networks incurred between diet, microbiome, metabolism, immunity, pharmaceuticals and nutritionals. In doing so, the BTI team strongly invokes a holistic approach to successfully advance drug discovery in the precision medicine era.
iMed: intelligent Medicine
The advanced analytics platform, intelligent Medicine (iMED), is engineered to model from molecules and cells to clinical cohorts of patients with inflammatory bowel disease (IBD).
iMED is the first multiscale modeling platform that ties together Ordinary Differential Equation (ODE), Stochastic Differential Equation (SDE), Partial Differential Equation (PDE), Agent-Based Model (ABM), and Artificial Intelligence (AI) modules into a single cohesive IBD model capable of parallel processing.
iMed is able to elucidate hidden, unforeseen linkages between spatiotemporal simulation changes with clinical disease scoring methods through image analysis of endoscopies. Combined with expert image analysis of real patient’s gut endoscopic images, advanced machine learning algorithms provide a foundation for clinical utility of our iMED models.
EHR Data Mining and Synthetic IBD Patients
Using large-scale clinical data in the form of electronic health records (EHR) and claims data from insurance plans of IBD patients, BTI is developing synthetic IBD patient cohorts (i.e., human avatars that capture human diversity and variation) to perform in silico clinical trials and engineer personalized/precision medicine strategies tailoring individual patients. We use structured electronic health records of 11,325 IBD patients since 1996 to perform deep phenotyping through utilization of unsupervised machine learning methods. The data elements extracted include demographic information (including age, sex, race, age at diagnosis), laboratory measures (133 laboratory variables, including more common variables such as glucose level to less common variables such as cortisol levels in serum or plasma), medication history (medication name, dosage and timing), co-morbidities (complete list of ICD9/10 codes), as well as information from GI clinic visits. Using EHR, it is possible to build predictive models of diseases and response to treatments for unseen conditions. Integrating EHR data with other sources of clinical and preclinical data can provide valuable opportunities for knowledge discovery by providing venues for building models that can predict non-intuitive hypotheses. AI involves advanced computer algorithms that replace the traditional rule-based strategy with data-driven approaches capable of learning from positive and negative experiences. As opposed to traditional “one-size-fits-all” treatments, AI algorithms are driving the future of predictive, preventive, precision medicine and provide personalized healthcare support for diverse and dynamic patient populations. On average, the EHR of a four-year patient contains about 32 petabytes of data. The application of AI will leverage the volume and exponential growth of clinical data to translate clinical information into new unforeseen insights for safer, more effective and cost-efficient personalized healthcare. Synthetic patient cohorts are key components in the design of in silico clinical trials. A virtual population group ideally reflects the individual diversity and variability plus characteristics that represent a clinical cohort population. The virtual population can be extremely useful in identifying the broad range of responses which are otherwise hard to predict in a clinical trial. A series of in silico clinical trials have been run based on de-identified clinical data of IBD cases. Data imputation was performed on the <250 samples of patient records. Machine learning (ML) methods were applied to predict INF-gamma, TNF-alpha, and CD Activity Index (CDAI) scores for the patients using profile information, lab measures, as well as medication history. A larger synthetic population of patient avatars was generated based on an expert guided random variation from the typical cases of IBD patients undergoing treatments of placebo, GED-0301, Anti-TNF-alpha, and BT-11. The EHR is used to create a training dataset for the prediction of CDAI scores of larger synthetic population of 10,000 patients using the optimized ML algorithm. From the different starting severity levels of CD, the statistically significant difference between the effects of the placebo versus all the drugs tested can be clearly seen (P < 0.05). For the highest range of initial CDAI scores from 450 to 500, BT-11 was statistically significant in outperforming GED-0301 and Anti-TNF-alpha in decreasing CDAI (P < 0.0001). These results suggest that BT-11 is the best drug option for treating the patients with moderate to severe IBD.
Personalized Nutrition
Around half of American adults have at least one chronic diseases, such as obesity and cardiovascular disease, which are often related to unhealthy diet and a sedentary lifestyle. Developing a healthy eating pattern in combination with an active lifestyle is vital to reduce the risk of disease and maintain health. Elevated blood glucose level is a major risk factor of diabetes. In a recent study, researchers from Weizmann Institute of Science measured responses (glucose levels) of 800 persons to 46,898 meals. It was found that the glucose levels can vary drastically in response to identical meals, indicating that the current, “one-size-fits-all”, dietary recommendations have limited value. Advanced analytics and big date related to nutrition, psychological sciences, and a growing demand from consumers for personalized products and services for improving human health lead to the need for personalized nutrition. We will leverage consumers’ data from food providers, distributors, retailers, smart devices, and healthcare provider to elucidate interactions among food/nutrition, human body (in particular human genome and intestinal microbiota), human behavior, and environment, based on which to prescribe food tailored to specific needs of the individual.
Informatics
Disruptive precision medicine technology conquering inflammation and diabetes
Informatics Overview
BTI Informatics is a division of Biotherapeutics Inc. that advances novel precision medicine informatics to identify cures for infectious and inflammatory diseases and diabetes. Combining and analyzing massive amounts of data of different types can often provide insights of great value. BTI has streamlined a pipeline that fully integrates computational and experimental platforms to transcend current limitations in clinical research (www.modelingimmunity.org).
Precision Medicine
Precision medicine under the BTI Informatics division assists:
Patients
BTI’s informatics platform uses state-of-the art computing to improve the quality of diagnosis and minimize time-to-care for patients suffering from infections, inflammation, diabetes or metabolic syndrome. Enhanced diagnosis is synergized with clinicians’ increased understanding for best treatment options.
Precision Medicine Clinicians
BTI’s precision modeling platform empowers clinicians to define patient populations appropriate for precision medicine applications, while determining optimum treatment patient plans through management and interpretation of big data. Next generation sequencing data substantially increases the knowledge base for infectious, immune-mediated and inflammatory diseases.
Researchers
BTI’s informatics platform seamlessly integrates diverse multi-parameter datasets to help researchers examine enormous amounts of data more efficiently and more accurately. This rigorous analysis helps researchers justify project leads, ensure reproducibility and advance along the drug discovery pipeline, and preemptively identifying safety and efficacy issues of products.
Technology
Our cutting-edge technology assembles data from the molecular, cellular, tissue and population levels using data-driven tools to provide answers to complex biological questions. BTI’s precision medicine and health strategies optimizes scalable and rigorous modeling and big-data analytics methods to gain mechanistic insights from molecules to health outcomes. BTI’s technology leverages the expertise gained through the Center for Modeling Immunity to Enteric Pathogens (www.modelingimmunity.org).
Company
The next frontier of personalized medicine and health
About Us
Mission, Vision and Values
Mission
BTI develops safer and more effective nutritionals and therapeutics for autoimmune and metabolic diseases.
Vision
BTI strives to create personalized nutritionals, therapeutics and informatics solutions that transform healthcare.
Values
Integrity, Passion, Creativity, Innovation, Teamwork.
Our Purpose
Biotherapeutics Inc. (BTI) is a science-based biotechnology company that integrates nutraceuticals, pharmaceuticals and informatics to advance precision medicine for preventing and treating autoimmune and metabolic diseases.
History
Dr. Josep Bassaganya-Riera, Virginia Tech professor and director of the university’s Nutritional Immunology and Molecular Medicine Laboratory (NIMML), recognized the impact his lab’s innovative research could have on public health, but he lacked the vehicle to take it from research to product. Joining with others in 2008, he formed BioTherapeutics, Inc. BTI soon demonstrated the value of the university-industry link by developing BT-11, an orally active, first-in-class therapeutic for Crohn’s Disease (CD) and abscisic acid (ABA), a food ingredient for glycemic control. New products are in the pipeline.